Provided by Tiger Fintech (Singapore) Pte. Ltd.

vTv Therapeutics

20.99
-1.7500-7.70%
Pre-market: 22.831.84+8.77%04:25 EDT
Volume:94.52K
Turnover:2.07M
Market Cap:54.83M
PE:-3.00
High:23.61
Open:21.60
Low:20.20
Close:22.74
Loading ...

Alliance Global says clinical hold lift ‘de-risking’ event for vTv Therapeutics

TIPRANKS
·
Yesterday

BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, PepsiCo, Blue Owl Capital

Reuters
·
Yesterday

vTv Therapeutics Soars 43% as FDA Lifts Clinical Hold on Diabetes Drug Trial

GuruFocus.com
·
Yesterday

VTv Therapeutics Shares Rise After FDA Lifts Hold on Diabetes Treatment

Dow Jones
·
17 Mar

BUZZ-vTv jumps after FDA lifts clinical hold on diabetes therapy

Reuters
·
17 Mar

vTv Therapeutics Shares up 22.6% as FDA Lifts Clinical Hold on Development of Co's Diabetes Therapy

THOMSON REUTERS
·
17 Mar

Vtv Therapeutics Says FDA Lifts Clinical Hold on Cadisegliatin Program for Diabetes; Shares Up Pre-Bell

MT Newswires Live
·
17 Mar

vTv Therapeutics says FDA has lifted clinical hold on cadisegliatin program

TIPRANKS
·
17 Mar

vTv Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview

Reuters
·
07 Mar

vTv Therapeutics Inc - Steven Tuch to Resign as CFO Effective March 21

THOMSON REUTERS
·
28 Feb

vTv Therapeutics CFO Steven Tuch to Resign

TIPRANKS
·
28 Feb

We're Keeping An Eye On vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Rate

Simply Wall St.
·
02 Feb

vTv Therapeutics initiated with a Buy at Alliance Global Partners

TIPRANKS
·
09 Dec 2024

Cantex Pharmaceuticals Receives FDA Orphan Drug Designation for Azeliragon for the Treatment of Brain Metastasis From Breast Cancer

THOMSON REUTERS
·
09 Dec 2024

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

PR Newswire
·
09 Dec 2024

vTv Therapeutics Inc : Alliance Global Partners Initiates Coverage With Buy Rating; Target Price $35

THOMSON REUTERS
·
09 Dec 2024